

Guangwu Zhu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8394111/publications.pdf>

Version: 2024-02-01

15
papers

1,480
citations

759055

12
h-index

996849

15
g-index

15
all docs

15
docs citations

15
times ranked

2001
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>BRAF</i> V600E and <i>TERT</i> Promoter Mutations Cooperatively Identify the Most Aggressive Papillary Thyroid Cancer With Highest Recurrence. <i>Journal of Clinical Oncology</i> , 2014, 32, 2718-2726.	0.8	595
2	Mortality Risk Stratification by Combining <i>BRAF</i> V600E and <i>TERT</i> Promoter Mutations in Papillary Thyroid Cancer. <i>JAMA Oncology</i> , 2017, 3, 202.	3.4	217
3	Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer. <i>Nature Communications</i> , 2018, 9, 579.	5.8	140
4	Patient Age-Associated Mortality Risk Is Differentiated by <i>BRAF</i> V600E Status in Papillary Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 438-445.	0.8	102
5	The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3241-3250.	1.8	80
6	The Genetic Duet of <i>BRAF</i> V600E and <i>TERT</i> Promoter Mutations Robustly Predicts Loss of Radioiodine Avidity in Recurrent Papillary Thyroid Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 177-182.	2.8	78
7	BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment. <i>Journal of the National Cancer Institute</i> , 2018, 110, 362-370.	3.0	60
8	<i>BRAF</i> V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2787-2795.	0.8	58
9	<i>BRAF</i> V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 3228-3238.	1.8	36
10	<i>TERT</i> promoter mutation determines apoptotic and therapeutic responses of <i>BRAF</i> -mutant cancers to BRAF and MEK inhibitors: Achilles Heel. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 15846-15851.	3.3	31
11	Robust Thyroid Gene Expression and Radioiodine Uptake Induced by Simultaneous Suppression of BRAF V600E and Histone Deacetylase in Thyroid Cancer Cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 962-971.	1.8	29
12	<i>REC8</i> is a novel tumor suppressor gene epigenetically robustly targeted by the PI3K pathway in thyroid cancer. <i>Oncotarget</i> , 2015, 6, 39211-39224.	0.8	26
13	Therapeutic targeting of FOS in mutant <i>TERT</i> cancers through removing TERT suppression of apoptosis via regulating <i>survivin</i> and <i>TRAIL-R2</i>. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	13
14	Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness. <i>Oncotarget</i> , 2017, 8, 900-914.	0.8	12
15	Stage II Differentiated Thyroid Cancer Is a High-Risk Disease in Patients <45/55 Years Old. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 4941-4948.	1.8	3